Next |
home / stock / scyx / scyx message board
Subject | By | Source | When |
---|---|---|---|
Gap fills in the 1.8's, golden cross around | BooDog | investorshub | 04/24/2023 3:12:38 PM |
Buy orders getting triggered. Just watch | BooDog | investorshub | 04/12/2023 4:40:04 PM |
Placed a buy order at 3.39 and took | duderaja | investorshub | 04/04/2023 2:08:55 PM |
Check this out: | duderaja | investorshub | 04/03/2023 7:28:52 PM |
$SCYX: Hey, THANKS, Capt. S-L!!! (& best of | Invest-in-America | investorshub | 04/03/2023 6:41:25 PM |
You are doing great my friend! Sweet find. | subslover | investorshub | 04/03/2023 6:37:31 PM |
$SCYX: THANKS, Capt. S-L!!! | Invest-in-America | investorshub | 04/03/2023 2:28:29 PM |
NEWS SCYNEXIS Reports Fourth Quarter and Full Year 2022 | subslover | investorshub | 04/03/2023 1:04:04 PM |
More upgrades coming. | duderaja | investorshub | 03/31/2023 10:36:48 AM |
znewcar1: $SCYX 76% v52,1M c2.94 f32,656M H2.97 RL1.6 off 30 day | znewcar1 | investorshangout | 03/30/2023 8:47:44 PM |
SCYNEXIS, Maxim Raises Price Target To $10, GSK | BooDog | investorshub | 03/30/2023 8:00:05 PM |
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For | BooDog | investorshub | 03/30/2023 5:49:30 PM |
$SCYX: Well, at least I'm BANKING over here!! | Invest-in-America | investorshub | 03/30/2023 2:53:44 PM |
GSK and SCYNEXIS Announce an Exclusive Agreement to | BooDog | investorshub | 03/30/2023 12:41:45 PM |
FUNNY!!! (I was just being my silly, childish, | Invest-in-America | investorshub | 03/30/2023 12:41:32 PM |
Heard that your knee deep in fungi lol | subslover | investorshub | 03/30/2023 12:33:31 PM |
10-K next week probably. Nice reset. | BooDog | investorshub | 03/23/2023 2:54:45 PM |
Q4 and annual earnings should be due within | murocman | investorshub | 03/23/2023 1:56:27 PM |
I like this play. | enthalpy | investorshub | 03/23/2023 1:11:57 PM |
znewcar1: $SCYX 28% v14,5M c2.00 f32,6M H2.28 ML1.15 | znewcar1 | investorshangout | 03/22/2023 10:41:08 PM |
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to o...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-genera...
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results...